Suvorexant for Delirium Prevention in Cancer Patients
Trial Summary
The trial requires that you stop using any benzodiazepines, benzodiazepine receptor modulators, or first-generation antihistamines at least 72 hours before joining. Also, you cannot use strong or moderate CYP3A4 inducers and inhibitors during the trial.
Research shows that Suvorexant helped reduce delirium symptoms in cancer patients with sleep problems, as their delirium severity scores significantly decreased after taking the drug. Additionally, a meta-analysis suggests that Suvorexant, known for treating insomnia, may also help prevent delirium, although more consensus is needed.
12345Suvorexant has been studied for its safety in preventing delirium in hospitalized patients, including those with cancer, and has not shown any harmful effects in these studies.
12345Suvorexant is unique because it is primarily used as a sleep aid and works by blocking orexin receptors, which are involved in wakefulness. This mechanism may help prevent delirium, especially in cancer patients who experience sleep disturbances, making it different from other treatments that do not target sleep-related pathways.
12346Eligibility Criteria
This trial is for hospitalized cancer patients experiencing insomnia, which may lead to delirium. Participants should meet the study's inclusion criteria and not have any conditions that would exclude them from participating as per the trial's exclusion criteria.Inclusion Criteria
Exclusion Criteria